Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

CMS includes Cologuard in updated Medicare Advantage Star Ratings

Exact Sciences generated $99.4 million in revenues during 2016, a 152-percent increase

CMS Proposes Inclusion of Cologuard in Medicare Advantage Star Ratings

Exact Sciences to report $99 million in revenues, 150 percent growth for 2016

Cologuard Earns Positive Review from Blue Cross Blue Shield Association

Exact Sciences Joins Deloitte’s Technology Fast 500 as One of the Sector’s Fastest Growing Companies

Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option

Exact Sciences Appoints Jeff Elliott Chief Financial Officer

Exact Sciences' Cologuard Wins Prestigious Prix Galien Award for Best Medical Technology Product

Exact Sciences Completes 68,000 Cologuard Tests During the Third Quarter